Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker
Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker
复制标题
DOI：
10.3892/or_00000194
复制
发表时间：
2009-01-01
期刊：
影响因子：
4.2
通讯作者：
Yasui, Wataru
中科院分区：
文献类型：
--
作者：
Hayashi, Tetsutaro;Matsubara, Akio;Yasui, Wataru
再生胰岛衍生家族成员4(Reg IV)是癌症和炎症性肠病的候选标记物，与神经内分泌和肠道分化有关。我们已经报道了14%的前列腺癌(PCa)组织中REG IV免疫组织化学染色呈阳性。本研究采用免疫组织化学方法对101例肾细胞癌(RCC)和95例膀胱尿路上皮癌(UC)中REG IV的表达进行了研究。用嗜铬粒素A和突触素染色观察神经内分泌分化，用MUC2染色观察肠道分化。免疫组织化学染色显示，肾癌中未见Reg IV的表达，仅1例(1%)UC中有Reg IV的表达。95例UC患者中神经内分泌分化13例(14%)，肠道分化33例(35%)。在1例REG IV阳性的UC患者中，观察到MUC2染色。由于在PCa中经常发现REG IV的表达，我们也用酶联免疫吸附试验检测了PCa患者血清中的REG IV水平。前列腺癌患者血清REG IV浓度(n=38，平均值+/-SE，1.69+/-0.16 ng/ml)显著高于对照组(n=40，1.28+/-0.11 ng/ml，P=0.0199，Mann-Whitney U检验)。检测PCa的敏感性和特异性分别为34%(13/38)和90%(36/40)。这些结果表明，在主要的泌尿系肿瘤中，REG IV在PCa中频繁表达，血清REG IV是一种新的PCa生物标志物。
Regenerating islet-derived family, member 4 (Reg IV) is a candidate marker for cancer and inflammatory bowel disease and is associated with neuroendocrine and intestinal differentiation. We have reported that 14% of prostate cancer (PCa) cases are positive for Reg IV by immunohistochemistry. In the present Study, We performed immunohistochemical analysis of Reg IV in other major urological cancers, including 101 renal cell carcinoma (RCC), and 95 urothelial carcinoma (UC) of urinary bladder by immunohistochemistry. We also investigated neuroendocrine differentiation by chromogranin A and synaptophysin staining along with intestinal differentiation by MUC2 staining. Immunohistochemical analysis of Reg IV revealed no expression of Reg IV in RCC, and only one case (1%) of UC expressed Reg IV. Neither neuroendocrine nor intestinal differentiation was found in RCC. Among 95 UC cases, neuroendocrine differentiation was detected in 13 cases (14%), and intestinal differentiation was observed in 33 cases (35%). In one Reg IV-positive UC case, MUC2 staining was observed. Since Reg IV expression was frequently found in PCa, we also measured Reg IV levels in sera from patients with PCa by enzyme-linked immuno-sorbent assay. The serum Reg IV concentration in PCa patients (n=38, mean +/- SE, 1.69 +/- 0.16 ng/ml) was significantly higher than that in control individuals (n=40, 1.28 +/- 0.11 ng/ml, P=0.0199, Mann-Whitney U test). The sensitivity and specificity for detection of PCa were 34% (13/38) and 90% (36/40), respectively. These results suggest that among major urologic cancers, Reg IV is expressed frequently in PCa, and that serum Reg IV represents a novel biomarker for PCa.